Session

IBD (Posters)

NON-INVASIVE BIOMARKERS OF TYPE III COLLAGEN CROSS-LINKING REFLECT FIBROLYSIS IN CROHN'S DISEASE PATIENTS WITH A NON-STRICTURING AND NON-PENETRATING DISEASE BEHAVIOUR
NON-INVASIVE BIOMARKERS OF TYPE III COLLAGEN CROSS-LINKING REFLECT FIBROLYSIS IN CROHN'S DISEASE PATIENTS WITH A NON-STRICTURING AND NON-PENETRATING DISEASE BEHAVIOUR

IBD (Posters)  et al.

ASSESSMENT OF SARCOPENIA AND NUTRITIONAL STATUS IN A COHORT OF PATIENTS WITH CROHN’S DISEASE
ASSESSMENT OF SARCOPENIA AND NUTRITIONAL STATUS IN A COHORT OF PATIENTS WITH CROHN’S DISEASE

IBD (Posters)  et al.

ASSOCIATION BETWEEN INFLAMMATORY BOWEL DISEASE AND SPONDYLOARTHROPATHIES: FINDINGS FROM A NATIONWIDE STUDY IN SWEDEN
ASSOCIATION BETWEEN INFLAMMATORY BOWEL DISEASE AND SPONDYLOARTHROPATHIES: FINDINGS FROM A NATIONWIDE STUDY IN SWEDEN

IBD (Posters)  et al.

PROACTIVE MEASUREMENT OF FAECAL INFLIXIMAB IN ULCERATIVE COLITIS POTENTIALLY INCREASES THE ACCURACY OF DISEASE MONITORING AND HELPS TO ACHIEVE THERAPEUTIC TARGET
PROACTIVE MEASUREMENT OF FAECAL INFLIXIMAB IN ULCERATIVE COLITIS POTENTIALLY INCREASES THE ACCURACY OF DISEASE MONITORING AND HELPS TO ACHIEVE THERAPEUTIC TARGET

IBD (Posters)  et al.

A RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLINDED, CROSS OVER FODMAP PROVOCATION IN PATIENTS WITH ULCERATIVE COLITIS AND IRRITABLE BOWEL SYNDROME ON A LOW FODMAP DIET
A RANDOMIZED, PLACEBO CONTROLLED, DOUBLE BLINDED, CROSS OVER FODMAP PROVOCATION IN PATIENTS WITH ULCERATIVE COLITIS AND IRRITABLE BOWEL SYNDROME ON A LOW FODMAP DIET

IBD (Posters)  et al.

ATTITUDE OF PATIENTS WITH IBD TOWARD COVID-19 VACCINE IN SAUDI ARABIA
ATTITUDE OF PATIENTS WITH IBD TOWARD COVID-19 VACCINE IN SAUDI ARABIA

IBD (Posters)  et al.

PERFORMANCE OF SCREENING STRATEGIES FOR LATENT TUBERCULOSIS INFECTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: RESULTS FROM THE ENEIDA REGISTRY OF GETECCU
PERFORMANCE OF SCREENING STRATEGIES FOR LATENT TUBERCULOSIS INFECTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: RESULTS FROM THE ENEIDA REGISTRY OF GETECCU

IBD (Posters)  et al.

SZN1326, A WNT AGONIST, WAS SUPERIOR TO ANTI-IL12/23P40 AND ANTI-TNF-A ANTIBODIES IN RESTORING EPITHELIAL INTEGRITY AND MITIGATING COLITIS IN A CHRONIC DSS MODEL
SZN1326, A WNT AGONIST, WAS SUPERIOR TO ANTI-IL12/23P40 AND ANTI-TNF-A ANTIBODIES IN RESTORING EPITHELIAL INTEGRITY AND MITIGATING COLITIS IN A CHRONIC DSS MODEL

IBD (Posters)  et al.

RISK FACTORS AND EFFICACY OF BIOLOGIC THERAPY FOLLOWING ILEAL POUCH-ANAL ANASTOMOSIS AMONG PATIENTS WITH ULCERATIVE COLITIS: LONG-TERM DATA FROM A PROSPECTIVE COHORT
RISK FACTORS AND EFFICACY OF BIOLOGIC THERAPY FOLLOWING ILEAL POUCH-ANAL ANASTOMOSIS AMONG PATIENTS WITH ULCERATIVE COLITIS: LONG-TERM DATA FROM A PROSPECTIVE COHORT

IBD (Posters)  et al.

LOCAL MESENCHYMAL STEM CELLS INJECTION IN CROHN’S DISEASE STRICTURES: A PHASE I-II CLINICAL STUDY
LOCAL MESENCHYMAL STEM CELLS INJECTION IN CROHN’S DISEASE STRICTURES: A PHASE I-II CLINICAL STUDY

IBD (Posters)  et al.

EFFICACY AND SAFETY OF INTRAVENOUS VEDOLIZUMAB FOR TREATMENT OF CHRONIC POUCHITIS: RESULTS OF THE PHASE 4 EARNEST TRIAL
EFFICACY AND SAFETY OF INTRAVENOUS VEDOLIZUMAB FOR TREATMENT OF CHRONIC POUCHITIS: RESULTS OF THE PHASE 4 EARNEST TRIAL

IBD (Posters)  et al.

DIFFERENCES IN DIRECT HEALTHCARE COST UTILIZATION IN THE FIRST YEAR OF IBD DIAGNOSIS: A BINATIONAL STUDY
DIFFERENCES IN DIRECT HEALTHCARE COST UTILIZATION IN THE FIRST YEAR OF IBD DIAGNOSIS: A BINATIONAL STUDY

IBD (Posters)  et al.

TELEMEDICINE IS AN EFFECTIVE TOOL TO MONITOR DISEASE ACTIVITY IN IBD PATIENTS IN THE COVID-19 ERA: A SINGLE CENTRE EXPERIENCE BASED ON OBJECTIVE DATA
TELEMEDICINE IS AN EFFECTIVE TOOL TO MONITOR DISEASE ACTIVITY IN IBD PATIENTS IN THE COVID-19 ERA: A SINGLE CENTRE EXPERIENCE BASED ON OBJECTIVE DATA

IBD (Posters)  et al.

URINARY METABOLOME IN NEWLY DIAGNOSED TREATMENT-NAÏVE CROHN’S DISEASE PATIENTS: RESULTS FROM THE IBDOMICS STUDY
URINARY METABOLOME IN NEWLY DIAGNOSED TREATMENT-NAÏVE CROHN’S DISEASE PATIENTS: RESULTS FROM THE IBDOMICS STUDY

IBD (Posters)  et al.

ULTRASONOGRAPHIC SCORES FOR CROHN’S DISEASE ACTIVITY ASSESSMENT – STILL LAG BEHIND CEUS
ULTRASONOGRAPHIC SCORES FOR CROHN’S DISEASE ACTIVITY ASSESSMENT – STILL LAG BEHIND CEUS

IBD (Posters)  et al.

SMALL-BOWEL ANGIOECTASIA: DO THE FEATURES AND APPROACH REALLY MATTER?
SMALL-BOWEL ANGIOECTASIA: DO THE FEATURES AND APPROACH REALLY MATTER?

IBD (Posters)  et al.

GROUP-BASED TRAJECTORY ANALYSIS OF WEIGHT CHANGE IN AN INFLIXIMAB-TREATED COHORT OF INFLAMMATORY BOWEL DISEASE PATIENTS
GROUP-BASED TRAJECTORY ANALYSIS OF WEIGHT CHANGE IN AN INFLIXIMAB-TREATED COHORT OF INFLAMMATORY BOWEL DISEASE PATIENTS

IBD (Posters)  et al.

INFLAMMATORY BOWEL DISEASE PATIENTS WITH A FIRST DEGREE RELATIONSHIP BEAR STRIKING SIMILARITIES: A RETROSPECTIVE SINGLE CENTER OBSERVATIONAL STUDY
INFLAMMATORY BOWEL DISEASE PATIENTS WITH A FIRST DEGREE RELATIONSHIP BEAR STRIKING SIMILARITIES: A RETROSPECTIVE SINGLE CENTER OBSERVATIONAL STUDY

IBD (Posters)  et al.

THERAPEUTIC TARGETS IN PAEDIATRIC IBD: A RETROSPECTIVE ANALYSIS OF INTERMEDIATE GOALS BASED ON UPDATED STRIDE-II (SELECTING THERAPEUTIC TARGETS IN INFLAMMATORY BOWEL DISEASE) RECOMMENDATIONS
THERAPEUTIC TARGETS IN PAEDIATRIC IBD: A RETROSPECTIVE ANALYSIS OF INTERMEDIATE GOALS BASED ON UPDATED STRIDE-II (SELECTING THERAPEUTIC TARGETS IN INFLAMMATORY BOWEL DISEASE) RECOMMENDATIONS

IBD (Posters)  et al.

ASSOCIATION OF ENDOSCOPIC WITH HISTOLOGIC REMISSION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN CLINICAL REMISSION TREATED WITH ANTI-TNFA AGENTS
ASSOCIATION OF ENDOSCOPIC WITH HISTOLOGIC REMISSION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN CLINICAL REMISSION TREATED WITH ANTI-TNFA AGENTS

IBD (Posters)  et al.

Item 401 - 420 / 568
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
21
22 23 24 25 26 27 28 29